Treatment for renal cancer: Are we beyond the cytokine era?

Nature Clinical Practice Urology

Volumn 3, Issue 9, 2006, Pages 478-484

  Ramsey, Sara L ^a   Aitchison, Michael ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

Immunotherapy; Randomized controlled trial; Small molecule inhibitors; Survival; Trial design

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CYTOKINE; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; INTERFERON; INTERLEUKIN 2; LAPATINIB; MEDROXYPROGESTERONE ACETATE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, RENAL CELL; CYTOKINES; ENZYME INHIBITORS; HUMANS; KIDNEY NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 33748633169     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0581     Document Type: Review

References (33)

1. Coppin C et al. (2005) Immunotherapy for advanced renal cell cancer. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD001425
2. Dorr RT (1993) Interferon-α in malignant and viral disease. Drugs 45: 177-211
3. Steineck G et al. (1990) Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 29: 155-162
4. Kriegmair M et al. (1995) Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45: 758-762
5. Pyrhonen S et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859-2867
6. Medical Research Council Renal Cancer Collaborators (1999) Interferon-α and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Lancet 353: 14-17
7. Mickisch GHJ et al. (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet 358: 966-970
8. Flanigan RC et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655-1659
9. Elson PJ et al. (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310-7313
10. Motzer RJ et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540
11. Negrier S et al. (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 13: 1460-1468
12. Negrier S et al. (2005) Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial [abstract]. J Clin Oncol 23 (suppl): 4511
13. Bromwich E et al. (2004) The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91: 1236-1238
14. Blay JY et al. (1994) Pretreatment serum CRP and response to interleukin-2. Br J Cancer 69: 200-201
15. Fyfe G et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696
16. Yang JC et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132
17. McDermott DF et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141
18. Vogelzang NJ et al. (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11: 1809-1816
19. Negrier S et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272-1278
20. Negrier S et al. (2006) Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial [abstract]. J Clin Oncol 24 (suppl): 4536
21. Upton MP et al. (2005) Histological parameters of renal cell carcinoma response to interleukin-2 based therapy. J Immunother 28: 488-495
22. Atkins M et al. (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721
23. Atzpodien J et al. (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial. Br J Cancer 85: 1130-1136
24. Gleave M et al. (1998) Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 338: 1265-1271
25. Escudier B et al. (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 23 (suppl): 4510
26. Rini B et al. (2005) AG-013736, a multi-targeted tyrosine kinase receptor inhibitor, demonstrates anti-tumour activity in a phase 2 study of cytokinerefractory, metastatic renal cell cancer (RCC) [abstract]. J Clin Oncol 23 (suppl): 4509
27. Motzer RJ et al. (2004) SU011248, a novel tyrosine kinase inhibitor, shows antitumour activity in secondline therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial [abstract]. J Clin Oncol 22 (suppl): 4500
28. Ratain MJ et al. (2005) Final findings from a Phase II, placebo-controlled, randomised discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. J Clin Oncol 23 (suppl): 4544
29. Eisen T et al. (2006) Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival [abstract]. J Clin Oncol 24 (suppl): 4524
30. Hudes G et al. (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferonalpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cancer (adv RCC) [abstract]. J Clin Oncol 24 (suppl): LBA4
31. Motzer RJ et al. (2006) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 24 (suppl): LBA3
32. Flaherty K (2005) Close-up on new ECOG trial: How it could define paradigm for combination targeted therapy. Kidney Cancer Journal. 3: 14-21
33. Rini BI et al. (2004) Practice and progress in kidney cancer: methodology for novel drug development. J Urol 171: 2115-2121